The PE ratio for Castle Biosciences stock stands at 115.73 as of Jan 14, 2025. The calculation is based on the latest EPS of $0.22 and the stock price of $25.46 per share.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | 98.2 | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
CSTL Castle Biosciences Inc | 115.73 | $713.07M |
OPTN OptiNose Inc | N/A | $50.28M |
OPK Opko Health Inc | N/A | $1.01B |
ORGO Organogenesis Holdings Inc | N/A | $383.15M |
CSTL's price to earnings ratio is 115.73 as of Jan 14, 2025.
CSTL's PE ratio is high because its earnings per share (EPS) is low relative to its stock price.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jan 14, 2025), Castle Biosciences's share price is $25.46. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $0.22. Therefore, Castle Biosciences's PE ratio for today is 115.73. PE RATIO(115.73) = STOCK PRICE($25.46) / TTM EPS($0.22)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.